Allergen-specific immunotherapy (AIT) is both effective and safe for the treatment of allergic diseases. After the declaration of COVID-19 as pandemic, there are many guidelines and recommendations regarding the AIT have been published. There should generally be an interval of ~ 1 week between SCIT and COVID-19 vaccination. There is the lack of real-world data scientifically based evidence of clinically significant interactions between AIT and COVID-19 vaccine. In this survey, we aim to consider the patients regarding to the efficacy and safety of AIT and Covid-19 vaccination, present the real-life experience in the view of both patient and clinician side regarding to the Covid-19 and AIT.

IG Allergen Immunotherapy

Chair: Deniz Eyice Karabacak 

Secretary: Enrico Heffler